Hiromi Yoshida,^a Misa Teraoka,^a
Akihide Yoshihara,^b Ken
Izumori^b and Shigehiro
Kamitori^{a*}

^aLife Science Research Center and Faculty of
Medicine, Kagawa University, 1750-1 Ikenobe,
Miki-cho, Kita-gun, Kagawa 761-0795, Japan,
and ^bRare Sugar Research Center,
Kagawa University, Miki-cho, Kita-gun,
Kagawa 761-0793, Japan

Correspondence e-mail:
kamitori@med.kagawa-u.ac.jp

Received 9 May 2011
Accepted 27 July 2011

Overexpression, crystallization and preliminary X-ray diffraction analysis of L-ribose isomerase from *Acinetobacter* sp. strain DL-28

Acinetobacter sp. L-ribose isomerase (L-RI) catalyzes a reversible isomerization reaction between L-ribose and L-ribulose. To date, information on L-RI remains limited and its amino-acid sequence shows no similarity to those of any known enzymes. Here, recombinant His-tagged L-RI was successfully overexpressed, purified and crystallized. Crystals of His-tagged L-RI were obtained by the hanging-drop vapour-diffusion method at room temperature as two crystal forms which belonged to the monoclinic space group C2, with unit-cell parameters $a = 96.60$, $b = 105.89$, $c = 71.83$ Å, $\beta = 118.16^\circ$, and the orthorhombic space group $F222$, with unit-cell parameters $a = 96.44$, $b = 106.26$, $c = 117.83$ Å. Diffraction data were collected to 3.1 and 2.2 Å resolution, respectively.

1. Introduction

L-Ribose can serve as a precursor for the synthesis of L-nucleoside analogues, which are widely used as pharmaceutical compounds such as antiviral and anticancer drugs (Doong *et al.*, 1991; Wang *et al.*, 1998; Gumina *et al.*, 2001; Yun *et al.*, 2005). There has been great interest in L-ribose as a plausible industrial material; nevertheless, L-ribose is not abundant in nature and is known as a 'rare sugar'. Helanto and coworkers have reported a novel strategy for producing L-ribose from L-arabinose for this purpose by introducing L-ribose isomerase activity into L-ribulokinase-deficient *Escherichia coli* UP1110 and *Lactobacillus plantarum* BPT197 strains (Helanto *et al.*, 2009).

L-Ribose isomerase (L-RI) from *Acinetobacter* sp., which is able to catalyze a reversible isomerization reaction between L-ribose and L-ribulose, has been reported as a new enzyme and cloned (249 amino-acid residues; Shimonishi & Izumori, 1996; Mizanur *et al.*, 2001). To date, information on L-RI is limited. The amino-acid sequence of *Acinetobacter* sp. L-RI shows no similarity to those of any known enzymes. A BLAST search against the PDB revealed that the highest homology was with human cystatin A (P25S; PDB entry 1gd4; Shimba *et al.*, 2000), with a Max Score of 28.9, a Query coverage of 13% and an E value of 2.0, followed by human stefin A (PDB entry 1n9j; Staniforth *et al.*, 2001), with a Max Score of 28.5, a Query coverage of 13% and an E value of 2.9, and λ repressor (PDB entry 3bdn; Stayrook *et al.*, 2008), with a Max Score of 27.7, a Query coverage of 25% and an E value of 4.7.

Although a mannose-6-phosphate isomerase from *Bacillus subtilis* has been reported to have similar properties to L-RI (Yeom *et al.*, 2009), the two enzymes are considered to be genetically different based on amino-acid sequence. To elucidate the unique substrate recognition and catalytic mechanism of L-RI, which are expected to differ from those of the well known isomerases, an X-ray structural analysis is essential.

Here, we present the overexpression, purification, crystallization and preliminary X-ray diffraction analysis of recombinant His-tagged L-RI.

2. Materials and methods

2.1. Overexpression and purification

The L-RI gene of *Acinetobacter* sp. strain DL-28 (DDBJ accession No. AB062121; UniProt accession No. Q93UQ5) was subcloned from the previously constructed plasmid p8IR (Mizanur *et al.*, 2001) by the PCR method using as primers forward 1 (5'-GGCCATGGCAAGGACGTCGATTACTCGTCGCGAGTATG-3') and reverse 1 (5'-CCGGATCCGCTGATCGCGGTCTGAAGCCGCCCGGTGTT-3') containing *Nco*I and *Bam*HI sites (bold), respectively, and forward 2 (5'-CCGGATCCGCAAGGACGTCGATTACTCGTCGCGAGTAT-3') and reverse 2 (5'-CCAAGCTTCTAGCTGATCGCGGTCTGAAGCCGCCCGGT-3') containing *Bam*HI and *Hind*III sites (bold), respectively. The first PCR products digested with *Nco*I and *Bam*HI were inserted into the expression vector pQE60 (Qiagen, Valencia, California, USA) linearized with *Nco*I and *Bgl*II. In the same way, the second PCR products digested with *Bam*HI and *Hind*III were inserted into the expression vector pQE30 (Qiagen, Valencia, California, USA) linearized with *Bam*HI and *Hind*III. The newly constructed plasmid pQE60LRI or pQE30LRI was introduced into *E. coli* JM109 cells and was capable of producing a C-terminally His-tagged L-RI or an N-terminally His-tagged L-RI, respectively. DNA sequencing was performed with an ABI PRISM 310 genetic analyzer.

For both N-terminally and C-terminally His-tagged L-RI the cells were grown at 310 K in 2×YT medium containing 100 µg ml⁻¹ ampicillin until the culture reached an optical density of 0.4–0.5 at 600 nm. L-RI overexpression was initiated by the addition of 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and the cells were cultivated with the addition of 1 mM MnCl₂ at 293 K overnight. The cells harvested by centrifugation at 5000g for 10 min at 277 K were resuspended and sonicated in buffer (50 mM NaH₂PO₄, 300 mM NaCl pH 8.0). The sonicated sample was centrifuged (20 400g, 20 min, 277 K) and the resultant cell-free extract was applied onto an affinity column (HisTrap HP 5 ml, GE Healthcare Biosciences, Piscataway, New Jersey, USA) equilibrated with sodium phosphate buffer (50 mM NaH₂PO₄, 300 mM NaCl, 20 mM imidazole pH 8.0). After washing with the equilibration buffer, the protein was eluted with a linear gradient of 50 mM NaH₂PO₄, 300 mM NaCl, 500 mM imidazole pH 8.0. The purity of the eluted sample was confirmed by

SDS–PAGE. After dialysis against buffer solution (5 mM Tris–HCl pH 7.5) overnight, the L-ribose isomerase activity of both His-tagged L-RIs was assayed as reported previously (Shimonishi & Izumori, 1996). L-RI activity was determined by measuring the increase in a keto sugar, L-ribulose, using the cysteine–sulfuric acid–carbazole method (Dische & Borenfreund, 1951). The enzymatic reaction was started by the addition of 50 µl 50 mM L-ribose (final concentration of 5 mM) to a reaction mixture consisting of 350 µl 50 mM glycine–NaOH buffer pH 9.0, 50 µl 10 mM MnCl₂ and 50 µl of the enzyme solution. The mixture was incubated for 10 min at 303 K and the reaction was stopped by the addition of 50 µl trichloroacetic acid (10%). The amount of keto sugar in the reaction mixture was determined by the cysteine–sulfuric acid–carbazole method. One unit of activity represents the formation of 1 µmol L-ribulose within 1 min under the assay conditions. L-Ribose isomerase activity was only detected for the N-terminally His-tagged L-RI (referred to in the following as His-tagged L-RI). The purified His-tagged L-RI was concentrated to 13 mg ml⁻¹ using an Amicon Ultra-4 10 kDa Ultracel (Millipore, Billerica, Massachusetts, USA). Protein concentrations were determined by measuring the absorbance at 280 nm and using the absorption coefficient of 38 390 M⁻¹ cm⁻¹ calculated on the basis of the numbers of tryptophan, tyrosine and cysteine residues in the enzyme (Pace *et al.*, 1995).

2.2. Crystallization and X-ray data collection

Initial crystallization screening for His-tagged L-RI was performed using Index Screen (Hampton Research, California, USA) and Wizard I, II and III (Emerald BioSystems, Washington, USA) by the

Figure 1
SDS–PAGE of purified N-terminally/C-terminally His-tagged L-RI. Lane 1, purified C-terminally His-tagged L-RI; lane 2, molecular marker (labelled in kDa); lane 3, purified N-terminally His-tagged L-RI.

(a)

(b)

Figure 2
Crystals of His-tagged L-RI. (a) Form 1 in the absence of hexamminecobalt(III) chloride. (b) Form 2 in the presence of hexamminecobalt(III) chloride.

sitting-drop vapour-diffusion method in 96-well plates (Corning, New York, USA) at 293 K. Two crystal forms of His-tagged L-RI were found (forms 1 and 2). Data for form 1 were collected using a Rigaku R-Axis VII imaging system on a Rigaku MicroMax-007 HF rotating-anode (Cu $K\alpha$) X-ray generator with ValiMax optics (40 kV, 30 mA) at 100 K (Rigaku, Japan). Data collection for form 2 was carried out at KEK PF-AR NW12A (Tsukuba, Japan) at a wavelength of 1.0 Å using an ADSC Quantum 210 CCD detector at 100 K. Both crystals were directly flash-cooled in a cryostream of liquid nitrogen without

Table 1

Data-collection statistics for His-tagged L-RI.

Values in parentheses are for the high-resolution bin.

	Form 1	Form 2
X-ray source	MicroMax-007 HF	PF-AR NW12A
Temperature (K)	100	100
Wavelength (Å)	1.54178	1.0
Detector	R-Axis VII imaging plate	Quantum 210 CCD
Crystal data		
Space group	C2	F222
Unit-cell parameters		
<i>a</i> (Å)	96.60	96.44
<i>b</i> (Å)	105.89	106.26
<i>c</i> (Å)	71.83	117.83
β (°)	118.16	
Solvent content (%)	55.6	52.4
V_M (Å ³ Da ⁻¹)	2.8	2.6
No. of molecules per asymmetric unit	2	1
Data collection		
Resolution range (Å)	66.37–3.10 (3.21–3.10)	50.00–2.20 (2.28–2.20)
No. of measured reflections	37234	79673
No. of unique reflections	11573	15886
Completeness (%)	99.4 (98.3)	94.5 (80.6)
Multiplicity	3.2 (3.1)	5.3 (4.3)
$R_{\text{merge}}^{\dagger}$ (%)	21.0 (38.6)	8.4 (31.5)
Mean $I/\sigma(I)$	3.7 (1.9)	12.4 (3.7)

$\dagger R_{\text{merge}} = \sum_{hkl} \sum_i |I_i(hkl) - \langle I(hkl) \rangle| / \sum_{hkl} \sum_i I_i(hkl)$, where $I_i(hkl)$ is the i th measurement and $\langle I(hkl) \rangle$ is the weighted mean of all measurements of $I(hkl)$.

any additional cryoprotectant. Data were processed using *Crystal-Clear* (Rigaku, Japan) and/or *HKL-2000* (Otwinowski & Minor, 1997).

3. Results and discussion

The purity of the purified samples was confirmed by SDS-PAGE, showing a single band with an estimated molecular mass of 28.4 kDa for C-terminally His-tagged L-RI (257 amino-acid residues; eight residues, GSHHHHHH, were added at the C-terminus) and 28.7 kDa for N-terminally His-tagged L-RI (260 amino-acid residues; the initial two residues MT were replaced by 13 residues MRGSHHHHHHG-SA) (Fig. 1). However, L-ribose isomerase activity was only detected for the N-terminally His-tagged L-RI. Thus, we used N-terminally His-tagged L-RI (His-tagged L-RI) for crystallization.

Small thin crystals appeared in a few days in a droplet consisting of 1 μ l protein solution (13 mg ml⁻¹ in 5 mM Tris-HCl pH 7.5) and 1 μ l reservoir solution [0.2 M NaCl, 30% (v/v) PEG 400, 0.1 M HEPES pH 7.5; Wizard II condition No. 42] equilibrated against 100 μ l reservoir solution. For further optimization of the conditions, Additive Screen (Hampton Research, California, USA) was applied. Crystals with dimensions of 0.1 $\times$ 0.1 $\times$ 0.03 mm that were suitable for X-ray diffraction experiments were grown within a few days from a droplet consisting of 2 μ l protein solution (10–13 mg ml⁻¹ in 5 mM Tris-HCl pH 7.5) and 2 μ l reservoir solution consisting of 18–23% (v/v) PEG 400, 0.1 M HEPES pH 7.5, 0.16–0.2 M NaCl with or without 10–20 mM hexamminecobalt(III) chloride equilibrated against 450 μ l reservoir solution by the hanging-drop vapour-diffusion method in a 24-well plate (TPP, Switzerland), as shown in Fig. 2.

Two crystal forms of His-tagged L-RI were found (forms 1 and 2). Form 1 was obtained in the absence of hexamminecobalt(III) chloride, while form 2 was obtained in the presence of hexamminecobalt(III) chloride. Forms 1 and 2 of His-tagged L-RI diffracted to resolutions of 3.1 and 2.2 Å, respectively, without any cryoprotectant, as shown in Fig. 3.

Figure 3

Diffraction of His-tagged L-RI. (a) Form 1 with 3.1 Å resolution marked, (b) form 2 with 2.2 Å resolution marked.

Data sets for form 1 (3.1 Å resolution) and form 2 (2.2 Å resolution) were successfully collected as summarized in Table 1. The crystals belonged to the monoclinic space group *C2*, with unit-cell parameters $a = 96.60$, $b = 105.89$, $c = 71.83$ Å, $\beta = 118.16^\circ$, and the orthorhombic space group *F222*, with unit-cell parameters $a = 96.44$, $b = 106.26$, $c = 117.83$ Å, respectively. The asymmetric units of crystal forms 1 and 2 are expected to contain two and one molecules, with crystal volumes per unit molecular weight (V_M) values of 2.8 and 2.6 Å³ Da⁻¹, corresponding to solvent contents of 55.6 and 52.4%, respectively (Matthews, 1968). L-RI has been reported to be a tetrameric enzyme in solution (Shimonishi & Izumori, 1996) and our preliminary X-ray diffraction analysis showed that L-RI possibly forms a tetramer with 222 symmetry in the crystals. N-terminally His-tagged L-RI was successfully overexpressed and showed enzymatic activity; however, C-terminally His-tagged L-RI did not maintain enzymatic activity despite being adequately expressed. This may suggest that the C-terminal region is involved in the formation of the active enzyme.

Since there is no X-ray structure with significant sequence homology to L-RI, molecular replacement could not be applied. In order to determine the initial phase, we are currently preparing selenomethionine-substituted L-RI.

This study was supported in part by the fund for Characteristic Prior Research 2009–2011, Young Scientists 2010–11 and Specially Promoted Research 2010 from Kagawa University. This research was performed with the approval of the Photon Factory Advisory

Committee and the National Laboratory for High Energy Physics, Japan. We thank Dr Yukiko Nagai for her technical assistance with the DNA sequencing.

References

- Dische, Z. & Borenfreund, E. (1951). *J. Biol. Chem.* **192**, 583–587.
- Doong, S.-L., Tsai, C.-H., Schinazi, R. F., Liotta, D. C. & Cheng, Y.-C. (1991). *Proc. Natl Acad. Sci. USA*, **88**, 8495–8499.
- Gumina, G., Song, G.-Y. & Chu, C. K. (2001). *FEMS Microbiol. Lett.* **202**, 9–15.
- Helanto, M., Kiviharju, K., Granström, T., Leisola, M. & Nyyssölä, A. (2009). *Appl. Microbiol. Biotechnol.* **83**, 77–83.
- Matthews, B. W. (1968). *J. Mol. Biol.* **33**, 491–497.
- Mizanur, R. M., Takata, G. & Izumori, K. (2001). *Biochim. Biophys. Acta*, **1521**, 141–145.
- Otwinowski, Z. & Minor, W. (1997). *Methods Enzymol.* **276**, 307–326.
- Pace, N. C., Vajdos, F., Fee, L., Grimsley, G. & Gray, T. (1995). *Protein Sci.* **4**, 2411–2433.
- Shimba, N., Kariya, E., Tate, S., Kaji, H. & Kainosho, M. (2000). *J. Struct. Funct. Genomics*, **1**, 26–42.
- Shimonishi, T. & Izumori, K. (1996). *J. Ferment. Bioeng.* **81**, 493–497.
- Staniforth, R. A., Giannini, S., Higgins, L. D., Conroy, M. J., Hounslow, A. M., Jerala, R., Craven, C. J. & Waltho, J. P. (2001). *EMBO J.* **20**, 4774–4781.
- Stayrook, S., Jaru-Ampornpan, P., Ni, J., Hochschild, A. & Lewis, M. (2008). *Nature (London)*, **452**, 1022–1025.
- Wang, P., Hong, J. H., Cooperwood, J. S. & Chu, C. K. (1998). *Antiviral Res.* **40**, 19–44.
- Yeom, S.-J., Ji, J.-H., Kim, N.-H., Park, C.-S. & Oh, D.-K. (2009). *Appl. Environ. Microbiol.* **75**, 4705–4710.
- Yun, M., Moon, H. R., Kim, H. O., Choi, W. J., Kim, Y.-C., Park, C.-S. & Jeong, L. S. (2005). *Tetrahedron Lett.* **46**, 5903–5905.